Purpose: The aim of the present study was to evaluate the levels of circulating antibodies against desmoglein (Dgs) 1 and Dgs3 in serum samples from patients with pemphigus vulgaris (PV) and correlate these values to the clinical phenotype of the disease.
Materials and Methods: Serum samples were obtained from 25 patients with oral mucosal dominant PV (group II), 23 patients with mucocutaneous PV (group III), 15 PV patients free of clinical symptoms (group I) and 30 healthy donors. Antibody titres against Dgs1 and Dgs3 were measured with enzyme-linked immunoabsorbent assay (ELISA) using recombinant Dsg1 and Dsg3. The relationship between the clinical phenotype and Dgs1 or Dgs3 levels was examined using ordinal logistic regression.
Results: Serum samples from groups I and II were positive for antibodies against Dgs3. Positive anti-Dsg3 and anti-Dgs1 antibodies were detected in the mucocutaneous PV group. Antibody titres against Dsg3 correlated with the serum circulating antibodies and the disease progression. Dgs1 levels and clinical phenotype were not significantly associated.
Conclusions: The clinical phenotype of the disease is defined by the anti-Dsg autoantibody profile whereas the measurement of the anti-Dsg3 autoantibody levels should be considered as a reliable indicator of disease progression.
Keywords: pemphigus vulgaris, desmoglein 1, desmoglein 3, clinical phe